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Cancer cells display abnormal morphology, chromosomes, and metabolism. This review will focus on the metabolism of tumor
cells integrating the available data by way of a functional approach. The ﬁrst part contains a comprehensive introduction
to bioenergetics, mitochondria, and the mechanisms of production and degradation of reactive oxygen species. This will be
followed by a discussion on the oxidative metabolism of tumor cells including the morphology, biogenesis, and networking of
mitochondria.Tumorcellsoverexpressproteinsthatfavorﬁssion,suchasGTPasedynamin-relatedprotein1(Drp1).Theinterplay
between proapoptotic members of the Bcl-2 family that promotes Drp 1-dependent mitochondrial fragmentation and fusogenic
antiapoptotic proteins such as Opa-1 will be presented. It will be argued that contrary to the widespread belief that in cancer cells,
aerobic glycolysis completely replaces oxidative metabolism, a misrepresentation of Warburg’s original results, mitochondria of
tumor cells are fully viable and functional. Cancer cells also carry out oxidative metabolism and generally conform to the orthodox
model of ATP production maintaining as well an intact electron transport system. Finally, data will be presented indicating that
the key to tumor cell survival in an ROS rich environment depends on the overexpression of antioxidant enzymes and high levels
of the nonenzymatic antioxidant scavengers.
1. A Brief Prelude
Every biochemical reaction within living cells involves the
transduction of some degree of free energy that is ultimately
derived from the oxidation of dietary nutrients. Most of
this free energy is made biologically available as reversible
phosphorylation reactions involving adenosine triphosphate
(ATP) that is continuously being produced and utilized by
cells to drive thermodynamically nonspontaneous reactions,
such as ion transport, muscle contraction, protein synthesis,
and DNA replication. Just as an example of the stupendous
biological power, the amount of free energy transduced by
our body during light walking is about 3,18 × 10−3 W/g,
whichis roughly 16.000 times more thanthe fusionreactions
thattakeplaceintheSuncore[1].Itisknownthatphosphate
esteriﬁcation into ATP can occur by several processes
but the best known are the phosphocreatine-ATP shuttle,
glycolysis, and oxidative phosphorylation [2]. Oxidative
phosphorylation is capable of producing signiﬁcantly more
ATP per mole of substrate than glycolysis in reactions
completelydependentontheavailabilityofoxygen.However,
the utilization of oxygen by cells, albeit the advantages
of oxidative phosphorylation, is not without consequence,
since partially reduced oxygen intermediates, the so-called
reactive oxygen species (ROS) play key roles in cellular redox
homeostasis [3] that may have a role in tumorigenesis.
2.Mitochondriaand Bioenergetics
2.1. Fermentation, Pasteur, Warburg, and Crabtree. Fermen-
tation was the ﬁrst metabolic pathway to be fully known,
thanks to the key ﬁndings of many researchers such as
Louis Pasteur, who deﬁned the biological nature of the
process and Eduard Buchner, who showed that cell-free
extracts could carry out fermentation. Later, Otto Meyerhoﬀ
experimentally demonstrated that a process similar to fer-
mentation occurred in skeletal muscles, although generating
ad i ﬀerent ﬁnal product, lactate [4]. He also showed that,
in the absence of oxygen, glycogen was converted to lactate
and when oxygen was present lactate was converted back to
glycogen, establishing the cyclic nature of lactate metabolism
in muscles (the lactate shuttle). In the context of cancer,2 International Journal of Cell Biology
when cells that use glucose as the main substrate to drive
ATP synthesis are subjected to hypoxia, as happens to the
cells located in the center of the tumor mass, glucose
uptake and metabolism increase signiﬁcantly in order to
maintain cellular ATP levels. Since under limited oxygen
availability the oxidative phosphorylation machinery is not
fully operational, other pathways are recruited in order to
supplytheenergydemand.Thereversiblenatureofincreased
glucose uptake and metabolism when cells experiment
hypoxia is known as the Pasteur Eﬀect. Also relevant is the
reversiblerepressiveeﬀectofglucoseoverrespiration,known
as the Crabtree eﬀect [5]. Thus, in spite of a functional
oxidative phosphorylation machinery, most solid tumors
exhibit a reversibly switch of their metabolism towards
lactic fermentation, even under normoxia. Thus, contrasting
with the Pasteur Eﬀect, the limitation of respiration in
the Crabtree eﬀect is not due to oxygen availability, but
rather to an acute repressive signaling cascade triggered by
glucose over the mitochondrial function. For this reason,
sometimes the Crabtree eﬀect is also referred to as Reverse or
Inverted Pasteur Eﬀect. However, the molecular mechanisms
that underlie the Crabtree eﬀect remain elusive. Finally,
the long-term metabolic reprogramming that takes place
in many cancer cells and which bears on cancer is known
as the Warburg eﬀect [6]. Otto Warburg observed that
cancer cells displayed decreased respiration and enhanced
lactate production, suggesting that they depended mainly
on fermentative metabolism for ATP generation [7]. It is
commonly assumed that tumors manifesting the Warburg
eﬀect dosobecausetheoxidativephosphorylationmachinery
is somehow impaired. In this context a growing body of
evidence shows in fact that the oxidative phosphorylation is
preserved in many cancer cells, as will be discussed in the
following section. The point that should be stressed here
regarding the main diﬀerence between Crabtree and Warburg
eﬀects is that in the former the oxidative phosphorylation
is rapidly and reversibly downregulated by the repressive
eﬀect of glucose, whereas in the latter, there is a long-lasting
irreversible eﬀect favoring fermentation due to the increased
expression of proteins involved in glucose transport and
metabolism [5].
2.2. Mitochondria and the Processes of Energy Transduction.
Structurally, mitochondria are organelles enclosed by two
very distinct membranes: an outer membrane, moderately
selective, and an inner membrane which is protein rich
and highly selective. These compartments are structurally
and functionally diﬀerent. The tricarboxylic acid (TCA)
cycle enzymes are located within this compartment, whereas
the proteins that comprise the electron transport system
(ETS) occur in the inner mitochondrial membrane. The
redox reactions mediated by diﬀerent compounds from
ubiquinone to iron/copper-sulphur clusters, cytochromes,
and ﬁnally oxygen reduction to water (respiration) take
place at the inner mitochondrial membrane. Recently, an
eﬀort to identify the whole set of mitochondrial proteins in
diﬀerent tissues of mice, rat, and human demonstrated that
this organelle is composed of almost 1100 diﬀerent proteins
[8].
The ETS is essentially composed of proteins that contain
an array of redox centers making up the complexes com-
monly listed from I to IV [2]. It is important to mention,
however, that respiration can be promoted by multiple sites
of electrons entry to the ETS in which electrons converge at
the ubiquinone reduction (Q-junction) [9]. Importantly, the
freeenergyreleasedduringtheelectronstransportbytheETS
complexes is linked to the transport of protons across the
innermitochondrial membrane.Duetoitsprotonimperme-
able nature, an electrochemical gradient is established [10].
This electrochemical proton gradient has two components;
o n ec h e m i c a l( ΔpH) and the other electrical (Δψ)i nn a t u r e ,
which together represent the protonmotive force (pmf). The
free energy accumulatedin the formofpmf can be converted
to chemical energy by means of the complex molecular
motor activity of the F1Fo ATP synthase, which allows the
return of protons back to the mitochondrial matrix coupled
to ATP production [11]. pmf is important not only for
ATP synthesis but for many processes such as the control
of substrate transport to mitochondrial matrix, respiratory
rates [12], calcium homeostasis [13], ROS generation [14]
and heat production [15].
2.3. Redox Reactions in the ETS. The ﬁrst ETS redox centers
were described in the nineteenth century by Charles Mac-
Munn. In 1883, he found a peculiar pigment (myohematin)
in the muscle of insects, whose light absorption pattern was
quite similar to heme. MacMunn proposed the respiratory
nature of these pigments and suggested that they were
not derived from hemoglobin since they were found in
organisms that knowingly did not have it [16]. Decades later
the parasitologist David Keilin revisited the problem using
an ingenious device, the microspectrophotometer. During
his studies, Keilin found the very same four absorption
bands identiﬁed by MacMunn not only in the ﬂy, but in
Bacillus subtilis and in baker’s yeast. Keilin called the ubiq-
uitous colored pigments cytochromes. Eventually, Keilin also
determined that light absorption pattern of the four bands
changed distinctly when metabolic poisons were adminis-
tered, or when yeasts were deprived of oxygen. He concluded
that the intensity of light absorption bands resulted from the
cytochromes reduction. As a result, it became paramount to
understand how cytochromes supported respiration.
Besides heme-containing cytochromes, it is known today
that many distinct redox centers are involved in the electron
transport along the ETS such as the iron/copper-sulphur
clusters, the ﬂavin-containing enzymes, and ubiquinone.
These compounds diﬀer not only in composition, but also
in the number of electrons transported and their redox
potentials. An interesting feature of the ETS is the presence
of two mobile electron transfers: the nonproteic organic
molecule ubiquinone (UQ) and cytochrome c. Although
UQ is quite hydrophobic, it is highly mobile and promotes
the bridging between complexes I, II, Glycerol-3 phos-
phate dehydrogenase, and electron transfer ﬂavoprotein-
ubiquinone oxidoreductase with complex III [2]. Unlike the
cytochromes and iron/copper-sulphur clusters, UQ can be
reduced by two electrons, generating the fully reduced form
ubiquinol (UQH2). However, during its redox cycle, UQ canInternational Journal of Cell Biology 3
be partially reduced, generating an unstable ubisemiquinone
(UQ￿−) radical. Cytochrome c is a small heme protein which
is loosely bound to the inner mitochondrial membrane
and is responsible for the transport of a single electron.
Cytochrome c also participates as a major inducer of
apoptosis, when released by the mitochondria in response
to proapoptotic stimuli, such as calcium and oxidative
stress conditions [17]. Cytochrome c is bound to inner
mitochondrial membrane by means of a direct interaction
with cardiolipin which can be disrupted when cardiolipin is
oxidatively modiﬁed in redox imbalance [18].
The ETS complex I, or NADH:ubiquinone oxidoreduc-
tase, is considered one of the largest known membrane
proteins and can be visualized by electron microscopy, which
reveals its characteristic “L” shape [19]. The structure of
this huge protein complex was recently elucidated [20].
Complex I activity couples the transfer of two electrons from
NADH to ubiquinone, in parallel with the translocation
of four protons across the inner mitochondrial membrane.
This activity provides about 40% of the proton-motive
force generation coupled to mitochondrial ATP synthesis. In
mammals, complex I contains 45 subunits resulting in an
apparent molecular mass of about 1 MDa and it has been
implicated in many human neurodegenerative diseases.
Complex II, also known as succinate dehydrogenase,
converts succinate to fumarate, which is the only TCA cycle
reaction taking place at the inner mitochondrial membrane.
The electrons from succinate oxidation directly contribute
to UQ reduction and oxidative phosphorylation as well.
The elucidation of complex II structure revealed that the
architecture of its redox centers is arranged in a way
that prevents ROS production at the FAD site [21, 22].
Complex II contains four subunits, two of which are integral
membrane, while the other two face the mitochondrial
matrix, which contains covalently bound FAD and three
iron-sulphur clusters.
Glycerol 3-phosphate dehydrogenase (G3PDH) has two
isoforms, the cytosolic (cG3PDH) and the mitochondrial
(mG3PDH). The mG3PDH is bound to the inner membrane
facing the mitochondrial intermembrane space [23]a n d
transfer electrons generated from dehydrogenation of G3P
to UQ. The activity of this enzyme is closely associated to the
oxidation of cytosolic NADH from the glycolytic pathway,
regenerating the “pool” of NAD+ from glycolysis.
The other component of ETS contributing to electrons
entry is the electron transfer ﬂavoprotein-ubiquinone oxi-
doreductase (ETF-QO), which is an intrinsic membrane
protein located in the inner mitochondrial membrane. ETF-
QO contains an FAD molecule and a [4Fe4S] cluster. The
protein represents the only input site of the ETS for electrons
derived from nine ﬂavoprotein acyl-CoA dehydrogenases
and two N-methyl dehydrogenases, which are eventually
transferred to UQ [24]. Incidentally, of the four distinct ETS
electrons entry sites, only complex I contributes to the Δp,
as it couples the energy of electrons transport to the proton
translocation across inner mitochondrial membrane.
ComplexIII,alsocalledubiquinol:cytochromecoxidore-
ductase, couples the transfer of two electrons from UQH2to
cytochrome c generating a proton gradient across the inner
mitochondrial membrane. The redox centers involved in
complex III activity are the cytochrome b, which has two
heme type b (BL and BH), cytochrome c1, and the Rieske
iron sulphur protein [2Fe-2S] [25]. Complex III is a dimer.
Each monomer consists of 11 diﬀerent polypeptide subunits
yielding a total of 240kDa [25] .T h ep r e s e n c eo ft w oa c t i v e
sites in complex III is an essential feature for the operation
of Q cycle [26]. One of the sites is responsible for UQH2
oxidation and proton translocation to the intermembrane
space and is located near the cytoplasmic side of the
inner membrane (Qp). The other site is responsible for
reducing the UQ, capturing electrons from the inner side
of the membrane and is located near the matrix side (Qn).
Since UQH2 donates two electrons and the cytochromes
are reduced by only one, electron transfer from the UQH2
to complex III is bifurcated. The ﬁrst step comprises the
oxidation of UQH2 at the Qp site of complex III. One of
its electrons is transferred to the Rieske iron sulphur protein
while the other is transported to heme bL.T h e r ea r et w o
fundamental reasons for the passage of the two electrons
from UQH2 to cytochrome c1 and cytochrome b. The ﬁrst,
and more obvious, is the fact that UQ is reduced by two
electrons and two protons, while cytochrome c by a single
electron. The other is structural. Because the Rieske center
is mobile in complex III and directs the electrons to reduce
cytochrome c, eventually it returns back to the Qp site
[27]. Thus, at the same time, the Rieske center is close to
cytochrome c, and distant from the site receiving the Qp of
another UQH2 electron [25]. During the Q cycle, for each
pair of electrons, two protons are consumed from the matrix
and four protons are released into the intermembrane space,
promoting the net transport of two protons.
The electron present at the cytochrome c is then
transferred to the terminal ETS complex IV, also known
as cytochrome c oxidase. The mammalian complex IV is
composed of 13 subunits and contains several redox centers
such as two hemes, one cytochrome a and cytochrome a3,
and two copper centers, the CuA and CuB centers. In fact, the
site of oxygen reduction to water is composed of a binuclear
center which contains cytochrome a3 and CuB.C o m p l e xI V
catalyzes the transfer of four electrons from four reduced
cytochrome c to oxygen, completely reducing it to two water
molecules [28]. Oxygen reduction involves a complex redox
cycle in which CuA and CuB centers, as well as the heme a,
hemea3 andatyrosineresidueparticipate.Firstly,theoxygen
molecule binds to the enzyme complex at the heme a3-CuB
binuclear center on its fully reduced state in the following
redox conﬁguration: heme a3
+2-CuB
+1. In fact, molecular
oxygen binds to the binuclear center at the heme a3
+2 site
and then the bonds between oxygen atoms are disrupted in
such a way that one of the oxygen atoms remains bound to
heme a3 site and the other one, to the CuB center. During
this step, two electrons are transferred from the heme a3
+2 to
the oxygen atom bound, adopting the heme a3
+4 oxidation
state (ferryl). The other oxygen atom is reduced by means of
transfer of two electrons, one originating from CuB
+1 center,
which becomes CuB
+2, and the other one from the tyrosine
244 residue, which is cross-linked to histidine 240 where the
CuB is bound. In the next step, the tyrosine is regenerated4 International Journal of Cell Biology
with electrons from one reduced cytochrome c molecule
which is transferred via heme a. An additional electron
is transferred from one reduced cytochrome c molecule,
through heme a, to the heme a3
+4, which converts to its
+3 redox state. Complete enzyme regeneration is achieved
by further delivery of two electrons, from two reduced
cytochrome c molecules, through heme a, to the active site,
restoring the heme a3
+2 and CuB
+1 redox conﬁguration and
allowing each of the two oxygen atoms originally in oxygen
to dissociate as water. Interestingly, the very same site where
oxygen binds to the cytochrome c oxidase, the heme a3
+2 at
the binuclear center, is also able to bind other ligands such
as cyanide (CN-) carbon monoxide (CO) and nitric oxide
(NO), all of which are respiration inhibitors [2].
During the sequential redox reactions of electrons trans-
port along the ETS to their ﬁnal acceptor, molecular oxygen,
a signiﬁcant part of the energy is conserved as protons are
transportedfromthemitochondrialmatrixtotheintermem-
brane space, generating the Δp, speciﬁcally at the complexes
I, III, and IV. As proton transport is thermodynamically
unfavorable, coupling the energy released by the electrons
transport at complexes I, III, and IV overcomes the energy
barrier.
2.4. The Chemiosmotic-Dependent ATP Synthesis. The ETS-
dependent proton transport across the inner mitochondrial
membrane allows the Δp formation and represents the
ultimate energy source by which mitochondrial ATP is
synthesized [10]. One of the ﬁrst proposals was based on the
idea that electrons passage through the ETS would release
a ﬁnite amount of energy that would be trapped in the
form of a phosphorylated intermediate “X” which would
then transfer its “high energy phosphate” to ADP by speciﬁc
enzymes [29]. Initial eﬀorts to identify intermediate “X,”
which for a while was thought to be phosphohistidine, failed.
Then, a revolutionary idea was proposed by Mitchell
in 1961 [30]. Mitchell’s hypothesis was based on the
concept known as vectorial metabolism, which stated that
substrates could be transported across a membrane by an
enzyme with a particular orientation against a chemical and
electrical gradient. This could only be achieved if it was
coupled to another thermodynamically favorable reaction
suchasATP hydrolysis. Mitchell’s chemioosmotic hypothesis
explained mitochondrial ATP synthesis, which in several
ways resembles the fuel cell-type, and set the basis for
a concept hinging on the coupling of electron transfer
to ADP phosphorylation. The supramolecular organization
of the enzymes at the inner mitochondrial membrane is
an essential component to be considered in this proposal
and Mitchell referred to it as anisotropy. In essence, the
anisotropic enzymes would act as molecular charge splitters
across the inner mitochondrial membrane, in which the
redox reactions at the ETS complexes resulted in the
separation of protons and hydroxyl anions to each side
of membrane, creating the so-called protonmotive force
(Δp). As respiration proceeded, the resulting increase in
the Δp would drive the separation of protons and hydroxyl
anions at the active center of the ATPase, allowing ADP
and inorganic phosphate dehydration and ATP formation.
In addition, this ingenious proposal oﬀered explanations for
many other observations such as (i) the eﬀect of uncouplers,
(ii) the regulation of redox state of the ETS components
by the magnitude of the electrochemical potential, (iii) the
photochemical phosphorylation in chloroplasts, and (iv) the
swelling and shrinkage eﬀects on mitochondria associated to
the changes in the electrochemical potential. This hypothesis
was extensively validated experimentally, being eventually
consolidatedin1967afterMitchell’sanswerstothecriticisms
raised by Slater [10]. Although the respiration coupled to
ATP synthesis was mechanistically demonstrated, it did not
explainhowtheATPmoleculeswereproducedbytheATPase
using the energy accumulated in the form of Δp.
The fundamental basis of the mechanism by which the
F1Fo ATP synthase complex produces ATP at the expenses
of the Δp was made possible by the research conducted in
the Laboratories of Efraim Racker, John E. Walker, Paul D.
Boyer and many others. In fact, a mitochondrial ATPase
activity was directly involved in the mechanism by which
ADP phosphorylation is coupled to electron transport [31].
This complex was ﬁrst observed by electron microscopy
in the 1960s [32]. Two distinct subcomplexes were seen:
one associated to the inner mitochondrial membrane (Fo)
and the other facing towards the matrix (F1). Puriﬁcation
of the whole F1Fo A T Ps y n t h a s ew a sa c h i e v e da sw e l la s
and the characterization of both F1 and Fo activities [33].
In 1973, Paul Boyer observed that the exchange of labeled
oxygen between inorganic phosphate and water was not
blocked by uncouplers of oxidative phosphorylation, but
was inhibited by oligomycin (a compound that blocks F1Fo
ATP synthase activity). Interpretation of these results led to
the suggestion that ATP might be formed at the catalytic
site of this complex. Thus, a signiﬁcant part of the energy
transduced by oxidative phosphorylation is utilized to drive
the release of preformed ATP from the enzyme [11]. Later,
in 1977, Boyer advanced this concept by proposing an
alternating site model for oxidative phosphorylation, in
which ATP is formed at one site of the enzyme site, but is
transitorily tightly bound. This ATP was not released from
enzyme unless ADP and Pi bound a second enzyme site and
the ATPase complex became energized [34]. Therefore, net
ATP formation by oxidative phosphorylation occurs by a
cooperative mechanism involving alternate conformational
changes in the β subunits of F1, promoted by the passage of
protons through the Fo site of this complex [35].
The passage of protons from the intermembrane space to
themitochondrialmatrixmediatedbytheFo sitewoulddrive
a rotational movement of the whole Fo which, in turn, would
transfer the rotation movement to the γ subunit and then
to the β subunits at the F1 site. As the interactions between
the γ subunit and each one of the three β subunits are
unique, γ subunit rotation induces a speciﬁc conformation
in each of the β subunits (open, loose, and tight). When
the β subunit adopts an open conformation, ATP is released
from the enzyme and the active site becomes empty, while
the neighboring β subunit adopts a loose conformation,
binding ADP, and inorganic phosphate. Finally, the third β
subunit is in the closed conformation, expelling water from
its active site, allowing the thermodynamically spontaneous
ATP synthesis.International Journal of Cell Biology 5
2.5. Mitochondrial Redox Metabolism. Since a long time, it
was known that oxygen played essential biological func-
tions ranging from biomolecule modiﬁcation to cellular
respiration. However, life arose long before oxygen could
accumulate in the atmosphere in order to be utilized by
cytochrome c oxidase. In fact, evidence indicates that organ-
isms in the primitive Earth had simpler metabolic pathways
that were not able to fully utilize the energy contained in
nutrients. Also, the process of respiration seems to have
emerged before the occurrence of signiﬁcant amounts of
oxygen in the atmosphere, as a result of photosynthetic
activity. Evidence supporting this interpretation was derived
from microorganisms that utilize electron acceptors other
than oxygen. Examples are iron, sulfate, vanadium, and even
uranium. Along Earth’s evolutionary history, organisms that
were able to use the sunlight as an energy source to allow
water oxidation coupled to molecular oxygen production
had a clear advantage. From the energy perspective, oxygen
utilization allows a more eﬃcient use of the energy stored in
the nutrients through the process of oxidative phosphoryla-
tion. Thus, organisms lacking oxygen transport and storage
systems, relying simply on its diﬀusion to the inner parts
of its body, exhibited a growth rate that strongly limited
by oxygen availability. This idea seems to oﬀer an excellent
explanation for the large number of giant fossil records aged
approximately300millionyearsthatlivedwhenatmospheric
oxygen levels reached about 35%.
Oxygen is not an inert gas and its toxicity was ﬁrstly
reported by Paul Bert way back in 1878. He showed that
oxygenwastoxictoanumberofinvertebratesaswellasfungi,
germinating seeds, birds, and even other higher animals.
In the central nervous system of mammals, oxygen toxicity
was referred to as the “Paul Bert eﬀect.” The mechanisms
underlying cellular oxygen toxicity were further studied by
Rebecca Gerschman in 1954 who proposed that oxygen
potentiated cell death induced by X-ray irradiation [36].
The conclusion was that oxygen and ionizing radiation
share mechanisms that possibly involved the formation of
“oxidizing free radicals.” A free radical is deﬁned as any
atom or molecule that has at least one unpaired electron
in an orbital [37]. The term ROS is used to designate
not only oxygen-derived free radicals, but also nonradical
oxygen species that are capable to generate highly reactive
oxygen radicals, such as hydroxyl radical [37]. Because
free radicals have unpaired electrons, they tend to achieve
stability by donating or removing electrons from adjacent
biomolecules such as sugars, lipids, and proteins, resulting
in their structural modiﬁcation. The accumulation of altered
or damaged biomolecules by free radicals is associated to a
multitude of functional changes in cells, such as apoptosis,
mutations, inhibition of enzyme activities, and oxidative
stress [37].
Much of the biomedical interest regarding the ROS
are due their potential role in the pathogenesis of many
diseases and also in aging. In this regard, the seminal
work of Harman in 1956, established the well-known “Free-
radical theory of aging,” which stated that aging is a
result of chronic oxidative modiﬁcation of biomolecules
and structures within the cells that ultimately culminate
in death [38]. According to Harman, the cellular free
radicals would probably arise by reactions involving molec-
ular oxygen as a result of dehydrogenase activity. Later
in 1969, McCord and Fridovich made a central contri-
bution by establishing a link between biology and free-
radical chemistry. A copper-containing enzyme, previously
identiﬁed by Keilin in 1939 as hemocuprein, was found
to have a key activity of dismutating superoxide radicals
into oxygen and hydrogen peroxide in bovine erythrocytes
[39].
Most of the oxygen consumed by the cell is completely
reduced to H2O by cytochrome c oxidase. However, a
small portion of this is partially reduced by mitochondria,
generating ROS. Complexes I, II, and III of ETS are sources
of ROS. In fact, the ETS is not only capable of generating free
radicals such as the superoxide radical (O
￿−
2 ), but also ROS
such as hydrogen peroxide (H2O2). The ﬁrst demonstration
of mitochondrial ROS formation was made in 1966 by
Jensen, who showed that succinate and NADH were able to
support hydrogen peroxide formation and this was strongly
potentiated by the metabolic poison antimycin A [40]. In
the cell, ROS production usually occurs during electron
transport along ETS, however, some pathophysiological con-
ditions can increase mitochondrial ROS production because
they reduce the activity of ETS or decrease ADP content in
mitochondria leading to an increase in the magnitude of the
membrane potential, a condition associated with increased
ROS “leakage” [41]. Further developments have shown that
not only the oxygen pressure, but also the magnitude of the
membrane potential strongly aﬀected mitochondrial ROS
generation [42]. However, mitochondria are not the only
cellular source of ROS. NADPH oxidases, peroxisomes, and
endoplasmic reticulum also represent important sites of ROS
production.
The imbalance between ROS generation and removal
might lead to the so-called oxidative stress. The antioxidant
defenses found in biological systems to avoid oxidative
stress may be divided into preventive (inhibition of ROS
generation), scavengers (suppression of unpaired electrons),
and repair (repair of molecules damaged by ROS). The
UCPs and hexokinase bound to mitochondria act as pre-
ventive antioxidant systems, because both mechanisms aim
to reduce membrane potential, promoting mitochondrial
depolarization. Cancer cells as well are characterized among
other features, by a high expression of hexokinase bound
to mitochondria through the VDAC protein. Originally,
it was thought that the VDAC bound hexokinase had an
exclusive role in the maintenance of the high glycolytic
ﬂux typical of cancer cells, but similarly to the mouse
brain cells, hexokinase of tumor cells may also maintain
the redox balance through an ADP recycling mechanism
[43, 44]. The remaining two groups of scavengers are
enzymatic (enzymes like superoxide dismutase, catalase and
glutathione peroxidase) and nonenzymatic (α-tocopherol,
thioredoxin). Examples of the repair antioxidant defenses
are the poly (ADP ribose) polymerase (PARP) and aldehyde
dehydrogenase.6 International Journal of Cell Biology
3. ROS and Cancer
In the light of Otto Warburg’s original observations concern-
ing aerobic glycolysis, it became pertinent to ask whether
the mitochondria of tumor cells were functional or not. This
question is by no means easily answered and even after 85
years into the post-Warburg era, the issue remains conﬂict-
ing, or at best riddled with misconceptions. One example
of this situation is the oft repeated puzzlement about the
cancer cell’s selection of the less energy eﬃcient anaerobic
glycolysis over the more ATP-rich tricarborxylic acid cycle in
conjunction with oxidative phosphorylation. Actually, what
cancer cells frequently do is to combine the best of the
two pathways in order to sustain the intense proliferation
as well as the metastasis that accompanies the transformed
state. The glycolytic pathway does not just generate ATP
and lactate as the end product. Many of its intermediate
metabolites are recognizably anaplerotic in nature as is
the case of 3-phosphoglycerate which acts as a precursor
to serine, glycine, and cysteine synthesis, all of which are
essential for the anabolic condition seen in tumorigenesis.
Indeed, it has been recently shown that in human breast
cancer, one of the genes that consistently displays a gain
in copy number is phosphoglycerate dehydrogenase a result
that highlights the association between glucose uptake and
aminoacid synthesis [45]. Besides, it must be remembered
that glycolysis is a much faster process in terms of ATP
synthesis, so that when not hindered by limited amounts of
glucose, tumor cells are not badly oﬀ. When dealing with the
term functionality with regards to mitochondria it must be
taken into account that the organelles are a hub to many
essential cellular processes. Whilst mitochondria of tumor
cells may perform some functions as well as those from
normal cells others may be deﬁcient and thus there is a
need to specify which of these bear on cancer causally. This
question will be addressed below with emphasis on those
pathwaysthatareatthesametimeanomalousand,therefore,
amenable to interference by speciﬁc inhibitors, especially
those connected to the bioenergetics scenario associated to
cell transformation.
Functionality of the mitochondria has been addressed
in several ways. Many papers dealing with the properties
of the organelle, particularly when comparing tumor and
normal cells, approach the question in a rather loose and
sectored manner. For example, it is common to refer to the
physiological status of the mitochondria in terms of its mor-
phology, its respiratory function including ATP synthesis,
i t sr o l ea sr e g u l a t o r so fi n t r a c e l l u l a rC a 2+ homeostasis, or
as essential elements in the processes of cell proliferation
and apoptosis. Frequently in the literature, the mitochondria
are considered functional or not on the basis of analysis
that may not be entirely informative of the status of the
organelle. For example, in some cases, conclusions about
the integrity of mitochondria, or the cell as a whole, are
based solely on the ability of certain enzymes to reduce
tetrazolium salts and on the assumption that if the enzymes
are active, then the organelle and the cells are also viable.
Clearly, then, it becomes important to consider what weight
should one attribute to these individual parameters and
whether they could represent bona ﬁde markers regarding
the general health of the mitochondria and suﬃcient to
classify them as dysfunctional. Perhaps a better description
forthesupposedlyaberrantbehavioroftheorganelleswithin
the context of malignant transformation would be “deviant.”
The questions that naturally follow this initial discussion
are deviant mitochondria are the cause or consequence of
cancer? If mitochondria are in fact key elements in cell
transformation, which alterations predispose cells to cancer?
3.1.Morphology. Itis not simple todeﬁne whatis the normal
morphology of mitochondria, mainly because they exhibit
considerable plasticity and change their shape radically even
when functioning within normal cells. Mitochondria may
display transient shape changes as a result of energy demand,
that is, oxidative phosphorylation (OXPHOS). A condensed
appearance has been associated to mitochondria actively
undergoing OXPHOS, whereas the orthodox conformation
reﬂected diminished oxygen consumption. Since in many
types of cancer cells the mitochondria have been shown
to respire normally, even though with less intensity than
glycolysis, it may be diﬃcult to observe morphologies that
diverge signiﬁcantly from the condensed appearance. In
otherwords,thecancer-relatedmorphologyofmitochondria
may be merely a reﬂection of the occurrence, or not of the
Warburg eﬀect (see below).
Morphology of the organelle refers also to the dynamic
processes of ﬁssion and fusion with one another and with
other organelles that mitochondria undergo in parallel
with the cell cycle. Mitochondrial fusion and elongation
produces a branched tubular network spreading throughout
the cytosol that characterizes what is generally known as
mitochondrial networking. Although the mechanism of
mitochondria ﬁssion, fusion and elongation, is not yet fully
understood, some of the key players in this process have been
identiﬁed and it was the analysis of these components that
suggested to a certain degree the distinction between normal
andtumorcells.Innormalcells,mitochondrialﬁssionoccurs
in synchrony with cell division. As the cells enter mitosis,
mitochondria too begin to fragment, an event which is
largely regulated by a GTPase dynamin-related protein 1
(Drp 1), a major component of the ﬁssion apparatus. The
ﬁssion machinery also requires the presence of hFis 1 which
is integrated in the outer membrane of the mitochondria. It
is thought that interaction between hFis 1 and Drp 1 alters
the conformation of the latter leading to the formation of a
constricting ring around the mitochondria which ultimately
produces fragmentation [46, 47]. In turn, Drp 1 activity
itself depends on posttranslational modiﬁcations, namely,
phosphorylation catalyzed by Cdk 1/cyclin. In addition,
the half-life of Drp 1can be modiﬁed. It is enhanced by
sumoylation by SUMO1 which protects Drp 1 from degra-
dation via proteasome and decreased by deSUMOylation
mediated by the protease SenP5. Incidentally, these reactions
illustrate quite well how mitochondrial ﬁssion responds
to elements that normally control the cell cycle and thus
becomes synchronous with cytokinesis. Exception should be
made to tissues in which cells do not proliferate, such as in
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components of the mitochondrial ﬁssion mechanism, recent
data have implicated other proteins as upstream regulators
of the Drp 1/hFis 1complex and hence of mitochondrial
networking [48, 49].
Upon completion of cytokinesis, mitochondria recon-
nect again through fusion, a complex event that involves the
merging of the double lipid membrane of the mitochondria.
This is mediated by profusion proteins located on the
surfaces of the inner and outer membranes, the complex
formedbetweenMgm1pandtheopticatrophyproteinOPA1
together with mitofusins (Mfn1 and Mfn2), respectively. The
mitofusins also play a role in tethering the mitochondria
to other organelles such as the endoplasmic reticulum [50].
This type of interaction does aﬀect Ca2+ signaling and
exempliﬁes how mitochondrial networking could have far
reaching eﬀects on metabolism as well. By the same token,
loss of Mfn2 is known to aﬀect the expression of the
subunits that make up the respiratory complexes leading
to reduced cellular oxygen consumption. Independently of
direct actions of mitofusins on mitochondrial tethering,
Mfn2 also regulates the ERK/MAPK signaling pathway a
feature that can have a direct bearing on tumorigenesis as it
will be discussed ahead [51].
So what is the consensus regarding mitochondria mor-
phology when comparing normal and tumor cells? Within
the context of mitochondrial networking, it has been pro-
posed that mitochondria of normal cells spend most of
their time in a fragmented mode (postﬁssion state) before
they fuse again [52, 53]. Along those lines it has been
reported that tumor cells also display a higher frequency
of fragmented mitochondria [54], which would indicate
the prevalence of ﬁssional events in those organelles. A
situation that could be considered analogous would be
apoptosis. Reports have shown that when cells are subjected
to overexpression of proapototic members of the Bcl-
2 family, they exhibit a higher rate of Drp-1-dependent
mitochondrial fragmentation and that over expression of
fusogenic proteins such as Opa-1 (promoting mitochondrial
fusion) protects from apoptosis [55, 56]. Our own results
conﬁrm this interpretation indirectly. The mitochondria of
H460 cellstreatedwithsodium butyrate,whichinhibited cell
proliferation, were shown to be more elongated than con-
trols. This was accompanied by a higher expression of Mfn1
suggesting that mitochondrial fusion could be associated to
lower rates of cell proliferation [57]. Taken together, the
data indicate that except for those cases in which oxidative
stressdirectlyinducesmitochondrialﬁssion[58],thebalance
between mitochondrial fusion and ﬁssion might depend
primarily on the proliferative (or apoptotic) status of the
cells. Along those lines, it would be interesting to compare
the variations of mitochondrial morphology in diﬀerent
types of synchronized cultures of tumor cells versus that of
the normal cell counterparts. In vivo, however, there would
be experimental complications since it is known that cell
doubling time and mitotic indexes are highly heterogeneous
even within tumors and also when diﬀerent types of cancer
are compared. In conclusion, so far the morphology of
mitochondria cannot be unequivocally associated to cell
transformation. The structural mitochondrial alterations
observed in many types of tumors cannot be ascribed to
any speciﬁc neoplasm and this question remains largely
unresolved.
3.2. Are Mitochondria of Tumor Cells Dysfunctional? Papers
that address the intermediary metabolism of tumor cells
typically begin the discussion by quoting the Warburg eﬀect
and usually mention that glycolysis replaces mitochondrial
oxidative phosphorylation as the principal source of cel-
lular ATP. Frequently, these opening remarks are followed
by statements that indicate that the high glycolytic ﬂux
adaptation occurs because the mitochondria of tumor cells
are dysfunctional or partially disabled. However, the aerobic
glycolysis described by Warburg did not imply that the mito-
chondria were dysfunctional since he himself acknowledged
that tumor cells continued to consume oxygen at levels
comparable to those of normal cells. In other words, what
Warburg really noted was that tumor cells did not exhibit the
Pasteur eﬀect, that is, glycolysis in tumor cells persisted even
in the presence of oxygen.
The longstanding notion that mitochondria are some-
how defective presumably derives from the fact that
researchers approach the problem in a nonholistic fashion
and frequently assume that if one set of results obtained
from tumor cells signiﬁcantly diﬀers from the normal
cell counterparts, other downstream events, even if not
investigated, will vary as well. Some metabolic modiﬁcations
have indeed been detected that when considered individually
justiﬁed the belief that the mitochondria of cancer cells were
somehowimpaired.Theseincludethepreferenceforparticu-
lar respiratory substrates, rates of electron transport, and the
activities of enzymes involved in oxidative phosphorylation
[59]. Albeit those early reports, data have accumulated to the
eﬀect that recently, there has been a shift in opinion. There is
now a tendency to accept that mitochondria of cancer cells
rarely present defects and seem to retain their capacity to
carry out oxidative phosphorylation and consume oxygen
with levels comparable to those of normal cells, much as
Warburg himself had stated [60]. According to this view,
the enhanced lactate production observed in tumor cells
does not necessarily imply the cessation of mitochondrial
activity,asconﬁrmedbyseveralexperimentsinwhichoxygen
consumption of cancer cells was evaluated. Such results also
indicate some degree of independence between cytoplasmic
glycolysis and mitochondrial metabolism acquired by the
tumor cells which may explain the absence of the Pasteur
eﬀect in cancer cells through the loss of a regulatory
interface. In this respect, it was shown that the cytotoxic
eﬀect of 2-deoxyglucose (2-DG) on A549 lung cancer cells
depended on inactivation of mitochondria in p53−/−cells.
The observation that the Warburg eﬀect was only evidenced
in cells in which mitochondria were impaired supported
the idea of a functional link between glycolysis and the
oxidative reactions of the organelle [61]. Furthermore, the
often quoted idea that in cancer cells the mitochondria
stop respiring in order to save carbon skeletons for the
biosynthesis of other biomolecules required for rapid growth
is not compatible with the observation that tumors actually
excrete high amounts of lactate [62]. That is not to say that8 International Journal of Cell Biology
the macromolecules and lipids found in the intramitochon-
drial milieu do not display alterations that while observable
may not signiﬁcantly compromise mitochondrial respiratory
function. The enhanced production of reactive species of
oxygen(ROS)andreactivenitrogenspecies(RNS)associated
to cancer cells (discussed in Section 3.3) can deﬁnitely cause
damage to proteins, DNA, RNA, and membranes. However,
the mutations produced in mtDNA are not necessarily
synonymous with tumorigenesis. It is known that germline
mutations of mitochondrial DNA can cause diseases that
aﬀect children and adults ranging from mitochondrial
myopathies to retinitis pigmentosa and possibly even to
autism, but not cancer. In an analogous manner, sporadic
mutations that may result from oxidative damage due to
elevated ROS in the mitochondria are suggested by many
to be the culprits of tumorigenesis. This has been diﬃcult
to demonstrate, however, mainly because there is no strong
evidence showing that the mtDNA mutations are driver
mutations. Also, the majority of somatic mutations found
in mitochondrial DNA are not harmful to the cells and
populationalsurveysshowedthatthesocalledspeciﬁccancer
mutations (varying from 30–100%) are frequently found
in mitochondrial DNA of individuals with no history of
cancer. Hence, it is thought that ROS-induced mtDNA
mutations may actually occur as a consequence of metabolic
reconﬁguration of cancer cells. Nevertheless, papers abound
that correlate the mitochondrial mutations to several types
of cancer [63].
How to resolve this quandary? There is a very tight
connection between the nuclear and mitochondrial genomes
coordinating the expression of exons encodings diﬀerent
subunits of proteins making up the electron transport chain.
Thus, it would be desirable to separate the individual
contributions of nuclear and mitochondrial DNA mutations
to the cancer phenotype. After the advent of the technique
of cytoplasmic hybrids (cybrids), or transmitochondrial
cybrids, it became possible to repopulate cells from which
mitochondria had been depleted, with exogenous mitochon-
dria present in enucleated cells. In this manner, the informa-
tion obtained from the fused cells, for example, cancer cells,
should highlight which events could be assigned to the mito-
chondria alone [64]. Results obtained with this experimental
approach have demonstrated that many of the respiratory
alterations ascribed to mitochondria of cancer cells (and
otherpathologies)couldbereproducedinthe“transplanted”
cells. For example, Imanishi and collaborators [65]w e r ea b l e
to show that mitochondrial respiration defects observed in
human breast cancer cells caused by mtDNA mutations were
responsible for the expression of high metastatic potential in
recipient cells. Interestingly, these experiments with cybrids
demonstrated that the mutated mtDNA aﬀected metastasis,
but not cell transformation. Results that conﬁrmed that
the increase in metastatic potential was acquired were also
obtained in a mouse model in which the transferred mtDNA
had a mutation in the NADH dehydrogenase subunit 6, a
deﬁciency that augmented the production of ROS. In these
experiments, the metastatic potential of the cybrids was
enhanced and use of a scavenger such as N-Acetyl cysteine
was able to counteract it [66]. Correlations exist showing
that ROS and RNS are able to inhibit the process of anoikis,
that is, the occurrence of apoptosis as a result of loss of
cell adhesion. In normal cells, anoikis prevents detached
cells from colonizing diﬀerent tissues. According to this, the
oxidative stress generated by ROS and RNS overproduction
in tumor cells would favor metastasis by means of activation
of prosurvival signaling pathways that in turn would inhibit
anoikis and in this manner boost the progression of cancer
[67]. It would be very interesting if it could be demonstrated
that alterations in the mtDNA alone and by extension
the higher production of ROS could be responsible for
metastasis. Other parameters such as diminished cellular
oxygen consumption and ATP synthesis observed in human
breast cancer cells could also be successfully passed onto the
cybrids and thus were ﬁrmly interpreted as derived from
mitochondria [68]. Diminished respiratory rates, except
when connected to damage or reversal of the electron
transport chain, however, would generate less ROS a result
which would go against the grain according to the canonic
view of ROS-induced tumorigenesis.
Although with the aid of the cybrid technology, the
role of mitochondria in tumorigenesis could be better
appreciated, caution should still be exercised to avoid
misinterpreting, or overstating certain selected parameters.
Some of those have limited information. For instance, when
studying mitochondrial respiratory control, values for the
P/O ratio, a very popular analysis, do not really deﬁne
whether mitochondria are functional or not since on its own
they reﬂect proton leak as a result in ﬂuctuations of states 3
and 4 of respiration. Others, as in the case of experiments
using isolated mitochondria, may result from manifestations
thatoccurindependentlyoftheregulatorygridthatnormally
control the organelles. Thus, experiments generating data
based on morphology (see Section 3.1)a sw e l la se v a l u a t i o n
of reactions to speciﬁc stressors have to be interpreted with
reservebecausetheyabrogatetheinnateresponsesconnected
to HIF-1α and hypoxia. In addition, when using intact cells
to investigate mitochondrial function, researchers have to
make use of detergents such as digitonin in order to allow
access of cell-impermeant substrates to the organelle. This
experimental resource may produce artifacts due to damage
to the mitochondria outer membrane resulting in the release
of components such as cytochrome c that in turn may trigger
cellularresponsesindependentlyofthebioenergeticsanalysis
being carried out. In a recent review, those questions have
beenclearlyandcarefullydissectedpointing outtheprosand
cons of each approach [69].
The importance of mitochondria as fully functional
organelles in cancer cells has been strengthened by consid-
ering the recently proposed hypothesis that metabolically
they actually conform to the orthodox model of ATP
production via the regular set of mitochondrial oxidative
reactions, like the TCA cycle, oxidative phosphorylation,
andtheanapleroticglutamineutilizationpathway.According
to this empirically based hypothesis, cancer cells are not
considered as rogue cells that become immortalized and
manage to live independently of other tissues. Reports have
described a lactate shuttle that is formed between stromal
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glycolytic, feed the latter, the oxidative tumor cells that
utilize mitochondria to their full capacity. This hypothesis
maintains that aerobic glycolysis, the hallmark of many
tumors, is actually carried out by the cancer associated
ﬁbroblasts rather than the cancer cells themselves [70, 71].
With the metabolic symbiosis thus established, the stromal
ﬁbroblasts would undergo autophagy and mitophagy and as
a result secrete and supply lactate to the cancer cells. In turn
the ﬁbroblasts would proﬁt from the available mitochondria
in the latter. This phenomenon was termed the “reverse
Warburg eﬀect” and the autophagy/mitophagy occurring in
the stromal ﬁbroblasts would be induced by oxidative stress
triggered by the cancer cells. The proponents of this model
went as far as mentioning that, in some cases, the Warburg
eﬀect might in fact represent an in vitro artifact. Although a
similar metabolic symbiosis seems to occur in normal cells,
it remains to be demonstrated whether the reverse Warburg
eﬀect could be extrapolated to other types of cancer [72].
At any rate lactate fueled respiration, a feature of metabolic
symbiosis, has been demonstrated in tumor cells in mice,
thusstrengtheningtheideaoftheinterdependencethatexists
between normal and tumor cells [73].
In conclusion, it can be safely stated that the mitochon-
dria of tumor cells are functional and that they may have
a signiﬁcant role in the maintenance of proliferation and
metastasis.
3.3. ROS and RNS Production in Tumor Cells. This section
tries to appraise the role of ROS and RNS in cancer forma-
tion. At the same time, it introduces the question whether
the oxidative stress signature of cancer cells can indeed be
a prime target for therapy. ROS and RNS can be regarded
as decidedly toxic to the cells by considering many of their
direct or indirect eﬀects on biomolecule targets. However,
toxicity,orforthatmattertheadjuvantroleincarcinogenesis
that ROS and RNS have appeared to depend ultimately
on their ﬁnal concentrations at a given instant and on the
duration of the stimulus. In consequence, ROS and RNS
levels depend on the regulation of the pathways that generate
them as well as those that degrade them (scavengers). When
R O Sa n dR N Sc o n c e n t r a t i o n sa r ew i t h i nac e r t a i nr a n g e
of the concentration gradient, “physiological” steady-state
levels of cellular ROS and RNS perform the housekeeping
coordination of metabolic and genetic processes. As such
H2O2, for example, stimulates cell proliferation by acting
as modulators of various transcription factors that in turn
inﬂuence several important cellular processes. Among the
transcription factors, NF-κB, Nrf2, p53, HIF-1α,a n dS T A T 3
could be mentioned. The mechanism whereby ROS modu-
late transcription factors involves the reversible oxidation of
cysteine residues of proteins belonging to signaling pathways
such as protein tyrosine kinases and phosphatases, lipid
phosphatases, proteases, and signaling eﬀectors. Exposure of
proteins to the oxidative environment generates dityrosine
residues that can be considered as oxidation markers. Apart
from its eﬀect on proliferation, H2O2 also mediates cell
diﬀerentiation and migration. As opposed to the physio-
logical role of ROS in normal cells, the oxidative stress is
characterized by situations in which the levels of molecular
oxygen or its ROS derivatives increase above the threshold of
normality and produce widespread irreversible oxidation of
aminoacids, polydesaturation of fatty acids, and mutations
on DNA and RNA. Mutations in nucleic acids occur by
formation of C5-OH and C6-OH adducts of thymine and
cytosine or similarly with purines, or by reaction with
the sugar moiety of the polymer leading in some cases to
single or double-strand breaks, intrastrand cross-links, and
protein-DNA cross-links [74–76]. This destabilizing eﬀect
of ROS on DNA can promote genomic instability which
as a consequence may predispose the cells to malignant
transformation. In this context, cancer cells that are able
to survive in a supposedly hostile microenvironment of
high ROS and RNS could be regarded as a subpopulation
that were selected in terms of their peculiar metabolic
adaptations. This view, however, is not without controversy.
Before discussing the possible mechanisms of adaptation, it
isrelevanttoinquirewhetherthereisaconsensusconcerning
the ROS associated etiology of cancer.
What then, if there is a pattern, is the ROS/RNS
phenotype of cancer cells? Are ROS and RNS able to act
as stimulants of cell transformation cells by subverting
the normal control network through a sustained oxidative
environment, or do they act directly producing harmful
modiﬁcations on lipids, proteins and RNA/DNA? Or both?
The earlier work of Szatrowski and Nathan [77] showed that
relatively large amounts of hydrogen peroxide, comparable
only to polymorphonuclear leukocytes and monocytes, were
produced by a number of tumors. Since then, the list has
grown and many reports indicate that cancer cells produce
massive amounts of ROS to levels that exceed the capacity of
the antioxidant enzymes that are normally in charge of ROS
detoxiﬁcation. Adding to this, there is evidence showing that
excessive ROS production causes the progressive inactivation
of the antioxidant enzymatic systems, a condition that favors
the maintenance of high concentration of ROS and the
induction of a chronic oxidative state. Results published
by several groups indicate that it is this situation that sets
the scene for transformation. According to this hypothesis,
the maintenance of parameters such as cell proliferation
within the boundaries of normalcy would depend primarily
on the redox balance established between ROS production
and the activity of antioxidant enzymes such as superoxide
dismutase, glutathione peroxidase, glutathione reductase,
catalase, and thioredoxin as well as the nonenzymatic
antioxidants scavengers glutathione and vitamins C and D.
In contrast, increased levels of ROS, that may result from
a failure of the antioxidant system rather than from over-
production, have been associated to chronic degenerative
conditionssuchascancer,aging,diabetes,andcardiovascular
diseases [78, 79]. The site of the oxidative stress has been
narroweddowntomitochondriaandwascoveredextensively
in a recent review [80] that highlights the prooxidant role of
the altered organelles as protagonists of tumorigenesis. Cor-
roborating this view, the high levels of ROS associated to the
pathophysiology of a wide variety of cancers have prompted
clinicians to examine the amount of dityrosine residues in
proteins exposed to an oxidative environment. Proteins that
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termed as advanced oxidation protein products (AOPP) and
currently serve as markers for monitoring cancer patients
[81]. Numerous other reports have generalized the notion
that cancer cells are more challenged by oxidative stress than
normal cells [82]. Among the types of cancer that have
been linked to increased oxidative stress are bladder, brain,
breast, cervical, gastric, liver, lung, melanoma, multiple
myeloma, leukemia, lymphoma, ovarian, pancreatic, and
prostrate [83]. In a number of reports, it has been found
that genes involved in oncogenic pathways and those linked
to tumor suppression are frequently mutated in transformed
cells all of them sharing the common feature of increased
amounts of ROS [84–88]. Finally, the hypothesis that ROS
and RNS are early eﬀe c t o r so ft u m o r i g e n e s i si si na g r e e m e n t
with data revolving around the inﬂammatory reactions. A
hegemonic view on the etiology of cancer states that when
an inﬂammatory condition lasts long enough it behaves as a
prodrome to cancer. The normal course of an inﬂammatory
reaction produced by a number of diﬀerent agents including
bacteria, carcinogens, and radiation progresses to a stage
in which mast cells and leukocytes are mobilized to the
sites of lesion. These cells produce what could be described
as respiratory bursts that in turn contribute towards the
increase in local production of ROS. The respiratory bursts
are actually ampliﬁed several fold by other inﬂammatory
cells attracted to the site of inﬂammation by chemokines
and cytokines released by the former cells, so that the
oxidative stress actually propagates to neighboring cells. In
this context, it is known that the extent of tumor associated
macrophage inﬁltrates correlates well with the prognosis of
certain types of cancer. If inﬂammation is not reversed, it
could then create a vicious circle whose outcome is chronic
ROS-induced oxidative stress and ultimately, cell transfor-
mation. The occurrence of inﬂammatory reactions with the
participation of cell inﬁltrates in premalignant senescent
hepatocytes has also been demonstrated in inﬂammation-
based mouse models of hepatocellular carcinoma [89].
One question could be raised concerning the increase
in ROS as an oncogenic factor. Why, in view of the known
roles of high ROS in inducing senescence and apoptosis,
cancer cells do not undergo apoptosis? Presumably in these
transformed cells the pathways connected to senescence and
apoptosis are somehow blocked. One proposed mechanism
for this inactivation involves p38 MAPK pathway. In normal
cells, it is known that elevated ROS induces apoptosis via
the p38α MAPK. In contrast, human cell lines in which
p38α is inactivated are refractory to ROS-induced apoptosis
which suggests that deﬁciencies in this pathway, as well as
those which involve p53 (often mutated in most cancers)
allow cancer cells to remain viable in the presence of
high ROS [90]. The question whether cancer cells survive
in a hostile ROS environment as a result of enhanced
activity of antioxidant enzymes and compounds must also
be considered.
Many papers attest to the fact that tumor cells are usually
well adapted to high levels of ROS and that their viability
is only possible due to enhancement of antioxidant activity
[60]. However, it should be borne in mind that tumor cells,
which occur in a tumor in diﬀerent stages of transformation,
should exhibit heterogeneous metabolic proﬁles. This would
be due to oncogenic gain-of-function and/or loss of tumor
suppressors. These alterations may generate a mosaic of
metabolic patterns resulting from diﬀerentially expressed
enzymes which in the same tumor would reveal increased
ROS levels and downregulated antioxidant systems. Such
a scenario is compatible with the model of waves of gene
expression proposed by Smolkov´ a and collaborators [5].
As alluded some ﬁndings cannot be generalized to all
types of tumors and to all situations. Some points that
require further discussion are listed below.
(a) Source of ROS: scientists do not agree as to the source
of ROS. Many reports state ﬂatly that mitochondria are the
main producers of ROS and highlight that organelle as the
site where the tumorigenic process begins [91]. Others call
attention to the fact that there are alternative and perhaps
more important intra- and extracellular ROS generating
reactions that include the endoplasmic reticulum, peroxi-
somes, the cytosol, plasma membrane, and the extracellular
space [92]. Among the most important nonmitochondrial
sources of ROS is the NADPH oxidase family of enzymes.
These are bound to the plasma membranes and to the
membranes of phagosomes. Of the seven oxidases that
comprise the NADPH family, Nox1, Nox2, and Nox4 are
expressed by several types of cancer cells, including colon,
prostate, gliomas, melanomas, pancreatic adenocarcinomas,
renal carcinomas, and ovarian. Other incidental nonmito-
chondrial sources of ROS include those that are generated
by external factors such as carcinogens and radiation that
are known eﬀectors of inﬂammatory reactions that usually
precede cell transformation (see below).
In the context of cancer, the NADPH oxidases should be
highlighted not only because of their quantitative contribu-
tions to ROS formation, but also as promoters of tumor-
induced angiogenesis, an important process adjuvant to
tumor growth and metastasis [93]. Supporting the role of
NADPH derived superoxides as promoters of tumor induced
angiogenesis,experimentshaveshownthatantioxidantssuch
as vitamins C and E reduced the expression of vascular
endothelial growth factor (VEGF) and vascular endothelial
growth factor receptor 2 (VEGFR-2) in mice [94]. Likewise,
in vivo experiments demonstrated that the scavenger NAC
was able to inhibit sarcoma-induced angiogenesis, thus
strengthening the ROS-induced tumorigenesis model [95].
(b) Are ROS tumorigenic? There is a growing consensus
as to the role of ROS in tumorigenesis. In many works,
ROS are clearly singled out as the main tumorigenic factors
[96, 97]. Some reports, however, indicate that ROS are
harmful and tumor cells are only able to survive thanks
to eﬃcient or exacerbated antioxidant defense systems [98,
99]. Put another way, mitochondria of tumor cells, which
as mentioned above are believed to be fully functional
and which according to many are the main producers of
ROS, play the simultaneous role of providing energy to
the cells, and also of introduce the tenuously controlled
oxidative stress, the sword of Damocles as it were [70].
Interestingly, ROS production seems to be much higher
in mitochondria in which damage to the respiratory chain
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electron transport, than those that are normally producing
ATP [100]. This situation illustrates then how the processes
of autophagy and mitophagy are beneﬁcial to the cells as
removers of potential sources of cell transforming ROS
[53]. Adding support to the toxic eﬀect of ROS to cancer
cells, it is worth mentioning that both, radiotherapy and
chemotherapy, normally employed to eradicate cancer cells
do so by producing ROS-mediated oxidative stress [97].
Although it is known that ROS have multiple downstream
eﬀects, what is emerging as an explanation to conciliate all
the conﬂicting data is that the overall outcome of the ROS-
triggered activations/inhibitions depends primarily on their
ﬁnal concentration. In order to even out the data in the
literature that show a wide variation in ROS concentrations
produced by diﬀerent types of tumor cells, it would be
important to show whether the observed oscillations are
actually due to the activities of antioxidant enzymes or the
presence of higher levels of free radical scavengers in these
cells.Thisseemstobethecaseofcancerstemcellsthatappear
to have lower level of ROS than normal cells [101]. Likewise,
hematopoietic systems display low levels of ROS although
the progenitor cells myeloid produce high levels of ROS. If
the hypothesis of antioxidants as the regulators of ROS and
hence as pace makers of tumorigenesis proves to be right,
the management of cancer should aﬀord many strategies of
interference based not only on the use of antioxidants, but
oninhibitorsactingonROSdownstreamsignalingpathways.
Distinction should be made among the ROS, however. Nitric
oxide (NO), for example, has been shown to have antipro-
liferative eﬀects in both, normal and tumor cells [102, 103],
and it has been demonstrated that superexpression of nitric
oxide synthase (iNOS) caused inhibition of proliferation
of pancreatic tumor cells. When considering the eﬀects of
ROS on transformed cells, another issue has to be taken
into account which involves the plasticity of tumor cells
regarding exposure to ROS. Results of experiments in which
tumor cells in culture were incubated in the presence of
increasing amounts of ROS showed that they responded
by displaying an enhanced tolerance to the oxidative stress.
Results obtained by Onul et al. [104] evidenced further
that A549 lung cancer cells adapted to long-term high
levels of hydrogen peroxide grew better in culture than
the parental cell line and were more resistant to the
chemotherapeutic agent Doxorubicin. Interestingly, those
adapted cells deﬁnitely favored a more anaerobic metabolic
proﬁle suggesting that the survival strategy adopted might
be independent of mitochondria. The same standing applies
forhighconcentrationsofnitricoxide(NO).Inbreasttumor
cell lines, high concentrations of NO were shown to induce
a phenotypic change [105]. Thus, it may well be that it is the
metabolic adaptation of tumour-initiating cells that could
dictate the development of cancer rather than HIF activation
or other signaling pathways that have been known to aﬀect
solid tumor growth. Whether the cells adapted to high ROS
would be resistant to antioxidant therapy remains to be
investigated. In conclusion, the individual contributions of
diﬀerent cell compartments to the ﬁnal ROS concentration
within the cells may predispose them to transformation,
mainly in those cases when the antioxidant systems are not
eﬀective in counteracting the oxidative stress. Excess of ROS
is also harmful to cancer cells.
3.4. Diﬀerent Tumors, Diﬀerent Biochemistries. Attempts to
build a grand unifying model of metabolic reprograming in
cancer cells that would make biochemical sense are perhaps
premature. As it became clear from the preceding discussion,
theavailabledatadonotalwaysﬁtintocoherentmechanisms
andsofarideasdonotconvergetoasinglestratagemtocom-
bat cancer cells. Apart from the controversies, experimental
diﬃculties,andconﬂictinginterpretations,thereareinherent
diﬀerences that have to be considered before one draws a
standard biochemical proﬁle analysis of diﬀerent tumors.
Firstly, normal tissues have individual metabolic rates that
would certainly inﬂuence the type of metabolism occurring
in the cognate transformed cells. Slow-twitch and fast-twitch
muscle tissue, for example, obtain ATP preferentially from
diﬀerent pathways. The same applies for several other tissues
in which the metabolic diversity reﬂects the presence of
s p e c i ﬁ ci s o f o r m so fe n z y m e s ,a so c c u r si nl i v e ra n db r a i n
tissue. It is plausible then to imagine situations in which
as a function of distinct metabolic rates, variable levels of
ROS would be produced that could cause diﬀerent types of
local lesions. Secondly, individuals are themselves diﬀerent
when considering their biochemical buildup. The emerging
ﬁeld of pharmacogenomics recognizes these diﬀerences
and the trend is now, taking advantage on available high
throughput technology, to carry out individual genome
and transcriptome analysis for patients undergoing long
term chemotherapy. However, biochemical diversity seems
to transcend genes. Population studies have suggested that
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